Antiviral activity of an ACE2-Fc fusion protein against SARS-CoV-2 and its variants.
SARS-CoV-2 has continued spreading around the world in recent years since the initial outbreak in 2019, frequently developing into new variants with greater human infectious capacity. SARS-CoV-2 and its mutants use the angiotensin-converting enzyme 2 (ACE2) as a cellular entry receptor, which has tr...
Saved in:
| Main Authors: | Ernesto Bermúdez-Abreut, Talia Fundora-Barrios, Diana Rosa Hernández Fernández, Enrique Noa Romero, Anitza Fraga-Quintero, Ana V Casadesús Pazos, Briandy Fernández-Marrero, Claudia A Plasencia Iglesias, Marilyn Clavel Pérez, Katya Sosa Aguiar, Belinda Sánchez-Ramírez, Tays Hernández |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2025-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://doi.org/10.1371/journal.pone.0312402 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
An ACE2-Fc decoy produced in glycoengineered plants neutralizes ancestral and newly emerging SARS-CoV-2 variants and demonstrates therapeutic efficacy in hamsters
by: Esther Föderl-Höbenreich, et al.
Published: (2025-04-01) -
Pharmacophore mapping of Angiotensin Converting Enzymes (ACEs): Insight to Binding Site of ACE1 and ACE2
by: Navista Sri Octa Ujiantari, et al.
Published: (2024-10-01) -
Computational Design and Evaluation of Peptides to Target SARS-CoV-2 Spike–ACE2 Interaction
by: Saja Almabhouh, et al.
Published: (2025-04-01) -
Potential Biomarkers in Pleural Effusions: ACE1, ACE2, and KLK12 Levels
by: Serkan Sen, et al.
Published: (2025-01-01) -
Inhibition of SARS‐CoV‐2‐mediated thromboinflammation by CLEC2.Fc
by: Pei‐Shan Sung, et al.
Published: (2023-05-01)